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Objectives. To determine whether the benefits outlined in
Background might extend to patients with multivessel disease, we
examined the short- and long-term outcome of multivessel
Palmaz-Schatz stenting.
Background. Percutaneous transluminal coronary angioplasty
(PTCA) has become the dominant treatment for most patients
with single-vessel coronary artery disease and has emerged as an
alternative treatment for selected patients with multivessel coro-
nary artery disease. Although multivessel angioplasty has excel-
lent early results and low procedural complication rates, long-
term outcome is tempered by the frequent need for repeat
revascularization. In patients with single-vessel coronary artery
disease, Palmaz-Schatz stenting has been shown to have a higher
success rate and a lower restenosis rate than conventional PTCA.
Methods. A total of 103 patients (mean age 64 6 11 years, 78
men and 25 women) underwent stenting of 212 vessels (saphenous
vein graft [53%], left anterior descending coronary artery [20%],
left circumflex artery [12%] and right coronary artery [15%]). In
88 patients (85%), multivessel stenting was performed during the
same procedure, whereas the remaining 15 patients (15%) had
staged multivessel stenting within 1 week of the index stent.
Stenting involved only native coronary arteries in 33 patients and
only vein grafts in 51 patients.
Results. Angiographic success was achieved in 102 patients
(99%). Major complications developed in three patients: one
patient died, and two patients had Q wave myocardial infarction,
with no emergency coronary artery bypass graft surgery or stent
thrombosis. Eleven additional patients (11%) developed non–Q
wave myocardial infarction, and nine patients (9%) had local
vascular complications requiring surgical repair. Clinical
follow-up was available in all patients at a mean of 13 6 8 months.
At 1 year, survival was 98%, with an event-free survival rate of
80%, reflecting predominantly repeat revascularization (17% over-
all, with 9% target site revascularization). Multivessel native
coronary stenting resulted in a higher event-free survival rate and
a lower probability of repeat revascularization than did multives-
sel saphenous vein graft stenting.
Conclusions. In selected patients, multivessel Palmaz-Schatz
stenting is technically feasible and carries both excellent early
results and favorable 1-year clinical outcome.
(J Am Coll Cardiol 1997;30:180–5)
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Percutaneous transluminal coronary angioplasty (PTCA) be-
gan as a treatment for proximal, noncalcified stenoses in a
single coronary artery (1). With advances in catheter design
and angioplasty techniques, availability of new devices and
increasing operator experience, PTCA has become the domi-
nant treatment for most patients with symptomatic single-
vessel coronary artery disease and has been extended to
selected patients with multivessel coronary artery disease
(2–6). Initial evaluation of multivessel angioplasty consisted of
descriptive studies (2–6) and retrospective matched studies
comparing it to coronary artery bypass graft surgery (CABG)
(7–9). Although these studies showed excellent early success
and low procedural complication rates, longer term outcome
was tempered by the need for repeat revascularization in 38%
to 47% of patients (2–9). Within the past 6 years, several
long-term, randomized trials comparing multivessel conven-
tional balloon angioplasty to CABG have been completed
(10–14), showing similar short- and intermediate-term (3 to 5
years) mortality, but a significantly higher (two- to threefold)
rate of repeat revascularization in the PTCA group (10–14).
The majority of percutaneous revascularizations performed in
these studies consisted of conventional balloon angioplasty,
because these studies predated U.S. Food and Drug Adminis-
tration approval of the Gianturco-Roubin stent (July 1993) and
the Palmaz-Schatz stent (August 1994).
The Stent Restenosis Study (STRESS) (15) and Belgian
Netherlands Stent study (BENESTENT) (16) trials have re-
cently demonstrated that Palmaz-Schatz stenting of single, de
novo lesions in native coronary arteries is associated with
greater early procedural success and lower incidences of
in-hospital events, angiographic restenosis and 1-year target
vessel revascularization (TVR) compared with conventional
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balloon angioplasty. In addition, Palmaz-Schatz stenting of
aortocoronary saphenous vein grafts (SVG) appears to have a
higher success rate and a lower restenosis rate than historic
balloon angioplasty controls (17). This raises the question of
whether the benefits of single-vessel stenting would extend to
multivessel intervention. Encouraged by favorable results of
multivessel Palmaz-Schatz stenting in a small group of patients
(18), we have continued to apply this approach to selected
patients. In this study, we report the early and 1-year outcome
of a 103-patient cohort who underwent multivessel stenting.
Methods
Study patients. Between July 1988 and December 1995,
more than 1,000 patients underwent Palmaz-Schatz stent
placement at Beth Israel Hospital in Boston. This includes the
103 patients described in this report, who underwent elective
placement of 273 Palmaz-Schatz stents in 212 vessels. Patients
were selected for multivessel stenting if they had significant
focal or tubular stenoses in more than one native coronary
artery or vein graft suitable for stent placement, as well as
evidence of myocardial ischemia. Exclusion criteria included
contraindication to antiplatelet or anticoagulation therapy;
poor distal runoff; small (,2.75 mm), diffusely diseased ves-
sels; involvement of a major (.2 mm) side branch; or signifi-
cant valvular disease.
Pharmacologic protocol. All patients received soluble,
nonenteric-coated aspirin (325 mg, continued indefinitely in an
enteric-coated form) and a calcium antagonist before the
procedure. In addition, 38 patients treated before August 1994
received dipyridamole (225 mg/d), and 65 patients treated
thereafter received ticlopidine (500 mg/d) for 1 month after
the procedure. Before August 1994, 1 liter of low molecular
weight dextran (Dextran 40) was infused starting 3 h before the
procedure and continued for 12 h after the procedure. During
the procedure, 10,000 U of heparin was administered intrave-
nously, with additional heparin given to maintain an activated
clotting time .300 s. After sheath removal, an infusion of
heparin was continued until warfarin therapy brought the
international normalized ratio to 2.0 to 3.0, where it was
maintained for 1 to 2 months.
Stent implantation and angiographic analysis. All patients
received Palmaz-Schatz stents (175 coronary stents and 98
biliary stents [19] [Johnson & Johnson Interventional Sys-
tems]). Lesions were predilated using an undersized balloon.
After deployment of the stent, full stent expansion was per-
formed using adjunctive high pressure (14 to 18 atm) balloon
(1.0 to 1.1 balloon/artery ratio) dilation as required, to achieve
,10% residual stenosis. Angiography was performed in two
orthogonal views. Each stented lesion was measured from an
optically magnified cine frame showing the lesion in its tightest
view, using the guiding catheter as a reference object. Mea-
surements were performed by using digital calipers (Fowler
Ultra-Cal II) and included guiding catheter diameter, proximal
and distal reference segment diameter and minimal lumen
diameter before and after stenting.
Follow-up. All patients were contacted by the investigators
at 6 weeks, 4 and 6 months, 1 year and then yearly thereafter
to assess for clinical events (death, myocardial infarction or any
revascularization). Repeat revascularization referred to any
revascularization (percutaneous or surgical) performed during
the study period. Revascularization was further categorized as
TVR and target site revascularization (TSR, defined as any
revascularization involving the stent itself or adjacent un-
stented vessel within 5 mm proximal or distal to the index
stent). Clinical follow-up was available for all 103 patients and
averaged 13 6 8 months (range 2.4 to 35.1). Follow-up for at
least 6 months was available in 93 patients (90%). Survival and
event-free survival were calculated from the date of the
procedure to the date of death or last follow-up.
Statistical analysis. Data are expressed as mean value 6
SD. Continuous variables were compared using the unpaired
Student t test, and categoric variables were compared by
chi-square analysis (20). Survival and event-free survival (free-
dom from death, myocardial infarction or repeat revascular-
ization) were estimated by Kaplan-Meier curves and compared
using the log-rank statistic (20,21). All p values were two-
tailed, and p # 0.05 was considered statistically significant.
Results
Patient characteristics. The study cohort consisted of 103
patients (78 men and 25 women) who underwent placement of
273 stents in 212 vessels (left anterior descending coronary
artery [LAD, 20%], left circumflex coronary artery [LCx, 12%],
right coronary artery [RCA, 15%] and SVG [53%]). The
baseline characteristics are summarized in Table 1. The pa-
tients’ mean age was 64 6 11 years. Seventy-two patients
(70%) had previous CABG, 17 patients (17%) had a recent
myocardial infarction and 60 patients (58%) had unstable
angina. In 88 patients (85%), multivessel stenting was per-
formed during a single procedure. Staged interventions (within
1 week) were performed in the remaining 15 patients (15%).
Multivessel stenting involved purely native coronary arteries in
33 patients (32%) and purely saphenous vein bypass grafts in
51 patients (49%). Treated lesions represented recurrence
after a previous intervention in 10% of vessels.
Early procedural outcome. Angiographic success (defined
as ,50% diameter stenosis with Thrombolysis in Myocardial
Abbreviations and Acronyms
CABG 5 coronary artery bypass graft surgery
LAD 5 left anterior descending coronary artery
LCx 5 left circumflex coronary artery
PTCA 5 percutaneous transluminal coronary
angioplasty
RCA 5 right coronary artery
SVG 5 saphenous vein graft
TVR 5 target vessel revascularization
TSR 5 target site revascularization
181JACC Vol. 30, No. 1 LAHAM ET AL.
July 1997:180–5 MULTIVESSEL PALMAZ-SCHATZ STENTING
Infarction trial [TIMI] flow grade 3) was achieved in 210
stented vessels (99%). Overall, stenting resulted in a reduction
in diameter stenosis from 79 6 14% to 2 6 8% (Fig. 1). One
patient (1%) died 2 days after successful stenting of two vessels
in the setting of cardiogenic shock, and two patients (2%)
sustained a Q wave myocardial infarction. Non–Q wave myo-
cardial infarction (peak creatine kinase, MB fraction 39 6
25 IU/liter [normal ,13 IU/liter]) occurred in 11 patients
(11%). No patient required emergency CABG, and neither
acute nor subacute stent thrombosis was observed. Nine
patients (9%) sustained local vascular complications requiring
surgical repair and 12 patients (12%) required blood transfu-
sion.
Long-term outcome. Clinical follow-up was available in all
patients and averaged 13 6 8 months (range 2.4 to 35.1).
Follow-up of at least 6 months was available in 93 patients
(90%). At most recent follow-up, 21 patients (21%) had
sustained major events: 4 patients (4%) died, 4 patients (4%)
had a myocardial infarction and 17 patients (17%) required
repeat revascularization. No patient required CABG. Of the
17 patients who underwent repeat revascularization of the
target vessel, nine (9%) had revascularization of the stented
site (TSR). At last follow-up, 81 patients (79%) were free from
angina.
The cumulative probability of overall survival (98% at
1 year) and event-free survival (80% at 1 year) is shown in
Figure 2 (Kaplan-Meier curves). The cumulative probabilities
of undergoing repeat revascularization or TVR (18% at 1 year)
and TSR (9% at 1 year) are shown in Figure 3.
Figure 1. Cumulative frequency of diameter stenosis at baseline and
after stent implantation for all 212 stented vessels.
Figure 2. Cumulative probability of overall survival and event-free
survival.
Figure 3. Patient-based probability of (top) repeat revascularization
(total revascularizations) and (bottom) TVR and TSR, defined as any
revascularization involving the stent itself or adjacent unstented vessel
within 5 mm proximal or distal to the index stent.
Table 1. Baseline Clinical Characteristics (n 5 103)
Age (yr) 64 6 11
Men/women 78/25
Location
SVG 112 (53)
LAD 43 (20)
LCx 26 (12)
RCA 31 (15)
Previous CABG 72 (70)
Hypertension 60 (58)
Diabetes mellitus 45 (44)
Hypercholesterolemia 70 (68)
Unstable angina 60 (58)
Recent MI 17 (17)
Data are presented as mean value 6 SD or number (%) of patients.
CABG 5 coronary artery bypass graft surgery; LAD 5 left anterior descending
coronary artery; LCx 5 left circumflex coronary artery; MI 5 myocardial
infarction; RCA 5 right coronary artery; SVG 5 saphenous vein graft.
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Multinative versus multi-SVG stenting. Multivessel stent-
ing was confined to saphenous vein bypass grafts in 51 patients
and to native coronary arteries in 33 patients (27 patients
underwent stenting of two vessels, and six patients underwent
stenting of all three native vessels). Their clinical characteris-
tics are detailed and compared in Table 2. These two groups
had similar baseline clinical characteristics, except that only
four patients (12%) in the native group had undergone previ-
ous CABG. The procedural success rate was 97% for the
native vessel group and 98% for the SVG group. Non–Q wave
myocardial infarction tended to be less common in the native
vessel group (three patients [9%] in the native vessel group vs.
seven patients [14%] in the SVG group, p 5 0.08). During
follow-up, fewer major events occurred in the native vessel
group compared with the SVG group (6% vs. 25%, p 5 0.01).
This difference reflected predominantly more repeat revascu-
larizations in the SVG group than in the native vessel group
(22% vs. 3%, p 5 0.04). This difference may be explained, in
part, by the slightly longer mean follow-up duration in patients
with multi-SVG stenting compared with multinative stenting
(14 6 9 months [range 2.4 to 35.1] vs. 10 6 8 months [range 2.6
to 30.9], p 5 0.06). At last follow-up, three (9.4%) of 33
patients with native coronary stenting and 13 (25.5%) of 51
patients with vein graft stenting reported angina (p 5 0.2).
Figure 4 shows that event-free survival was better for native
vessel treatment compared with SVG treatment (92% vs. 74%,
p 5 0.01). Although the cumulative probability of any subse-
quent revascularization was higher in the SVG group than in
the native vessel group (1-year repeat revascularization 23%
vs. 5%, p 5 0.01), the need for revascularization of the target
site was similar in the two groups (1-year TSR of 10% for SVG
and 5% for native vessels, p 5 0.5) (Fig. 5).
Discussion
Five randomized trials comparing multivessel conventional
PTCA to CABG have been published (10–14), all showing
similar rates of late (3 to 5 years) death or myocardial
infarction but higher incidences of angina and repeat revascu-
larization in patients treated with PTCA (10). The main
limitation of multivessel PTCA thus remains its substantial
need for repeat revascularization, generally driven by clinically
significant restenosis occurring within the first 6 to 12 months
of initial treatment. In patients with single-vessel de novo
native coronary lesions, Palmaz-Schatz stenting is associated
with a reduction in restenosis and TVR compared with con-
ventional PTCA (15–17). Extension of this approach to se-
lected patients with multivessel disease might thus reduce the
need for early repeat revascularizations and prolong the
symptom-free interval.
Figure 4. Cumulative probability of event-free survival for multinative
coronary stenting versus multi-SVG stenting.
Figure 5. Patient-based cumulative probability of repeat revascular-
ization (top) and TSR (bottom) for multinative coronary stenting
versus multi-SVG stenting.
Table 2. Multinative Versus Multi–Saphenous Vein Graft Stenting
Multinative
(n 5 33)
Multi-SVG
(n 5 51) p Value
Baseline characteristics
Age (yr) 64 6 12 65 6 11 NS
Men/women 23/10 40/11 NS
Unstable angina 18 (55) 35 (69) NS
Before CABG 4 (12) 51 (100) ,0.0001
In-hospital outcome
Q wave MI 0 (0) 1 (2) NS
Non–Q wave MI 3 (9) 7 (14) 0.08
Follow-up (months) 10 6 8 14 6 9 0.06
Events 2 (6) 13 (25) 0.01
Death 1 (3) 3 (6) NS
Repeat revascularization 1 (3) 11 (22) 0.04
Data are presented as mean value 6 SD or number (%) of patients.
Abbreviations as in Table 1.
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Over the last 5 years, we have applied multivessel stenting
to selected patients, many of whom (70%) had previous
CABG, which made percutaneous revascularization a more
attractive strategy than repeat CABG. Although the majority
of patients treated with stenting in our early experience
underwent stenting of a single vessel, the 103 patients in this
series represent 10% of our cumulative experience with stent-
ing to date. The 99% angiographic success rate and 3% major
complications rate (1% death, 2% Q wave myocardial infarc-
tion) underscore the high level of reliability that stenting offers
in the treatment of both native coronary and vein graft disease
(16–18,22–24). These early outcomes compare favorably with
previous reports of balloon angioplasty in which multivessel
disease and multivessel intervention were identified as predic-
tors of adverse events (2–4).
Randomized trials of conventional PTCA in multivessel
disease, however, have identified restenosis (requiring repeat
revascularization) and recurrent angina as the main limitations
of PTCA versus CABG. In the present analysis, the 1-year
repeat revascularization rate was 18% (5% for multinative
vessel and 23% for multi-SVG stenting). According to Kaplan-
Meier estimates, the 1-year overall survival rate was 98% and
the 1-year event-free survival rate was 80%. Of the repeat
revascularization procedures, all were percutaneous and only
9% were related to the stented site (TSR, 5% for native vessel
and 10% for SVG), reflecting the fact that repeat revascular-
ization was being performed mainly to treat progression of
disease at other sites, particularly after SVG stenting. These
TVR and TSR rates are similar to other reported series of
Palmaz-Schatz stenting (16–18,22–24). Most important, all
measures of 1-year clinical outcome (including survival, event-
free survival, freedom from myocardial infarction, TVR and
TSR) compared favorably with reported series of multivessel
angioplasty (2–13).
When the analysis is restricted to just the 33 patients who
underwent multivessel stenting limited to native coronary
arteries, the 5% one-year repeat revascularization rate is lower
than that reported for conventional PTCA in multivessel
disease. Even for those patients who underwent multivessel
stenting of saphenous vein grafts, the 23% one-year repeat
revascularization rate and 10% one-year TSR rate are excel-
lent for a subset of patients that characteristically has a high
(40% to 60%) restenosis rate (25), and below those rates seen
for both balloon angioplasty and directional atherectomy in the
Coronary Angioplasty Versus Excisional Atherectomy Trial
(CAVEAT II) (26).
Study limitations. This study has several important limita-
tions. First, because it represents an observational study, no
direct comparison with CABG or multivessel PTCA can be
made. Second, this study represents a highly selected subset of
patients with multivessel disease. A large proportion of pa-
tients with multivessel coronary artery disease are not eligible
for complete revascularization by stenting, because ,20% of
patients with multivessel disease were found eligible for con-
ventional PTCA in the randomized trials of PTCA versus
CABG (10–14) owing to disease in small, diffusely diseased or
totally occluded vessels. Thus, this cohort represents a select
minority of patients chosen for clinical and angiographic
characteristics favorable for stenting, which limits the extrap-
olation of its findings to the majority of patients with multives-
sel disease.
Conclusions. The present study demonstrates that in a
highly selected group of patients with multivessel coronary
artery disease suitable for stenting, this approach is technically
feasible, with excellent early results and a favorable long-term
clinical outcome. Larger, randomized trials comparing mul-
tivessel stenting to CABG are warranted to allow direct
comparison between these revascularization strategies.
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